Francisco Trust trustee Thomas Emalfarb sells 95,392 Dyadic International common shares worth $124,823.82PUBT·Jul 24 at 04:12 PMDYAI-6.19%
Dyadic Announces Continued Listing on the Nasdaq Capital Market | DYAI Stock NewsStockTitan·Jul 23 at 10:30 PMDYAI-6.19%
Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filingrttnews·Jul 21 at 10:25 PMASBP+3.95%DYAI-6.19%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jul 21 at 12:05 PMTELO-4.07%CPHI+5.69%
Dyadic grows bio-industrial pipeline with innovative enzyme program, boosting its offerings in industrial sector.Unusual Whales·Jul 16 at 07:00 AMDYAI-6.19%
Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdictrttnews·Jul 14 at 10:18 PMNXTC+5.86%ATAI+0.14%
Dyadic International shares are trading higher after the company announced continued progress across multiple global health collaborations validating its proprietary C1 protein production platform potential.benzinga_article·Jul 7 at 09:39 AMDYAI-6.19%
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential | DYAI Stock NewsStockTitan·Jul 6 at 10:25 PMDYAI-6.19%
